The following stories appear in full on Today's Vidyya Medical News Service Web site.
In one of the first "recycling" studies to examine people who attempt to quit smoking after first failing medical treatment, researchers at Oregon Health Sciences University and their colleagues found abstinence rates five times greater for participants taking bupropion compared to participants taking a placebo. Study results were presented at 12 p.m. on 24 March 2001, at the Society for Research on Nicotine and Tobacco Annual Meeting in Seattle.
For more information: OHSU Study Shows That Drug Therapy Can Help Smokers Quit, Even If They Have Failed Previously
One thing you can count on the Internet to do well is spread viruses and rumors. Here are the latest from the CDC's Rumors and Hoaxes website: Did a child die from a heroin overdose after finding a used syringe on the playground? Can AIDS be transmitted through contact with the material of a new, unused feminine (sanitary) pad? Is it true that the Weekly World News made claims that the CDC discovered a mutated version of HIV that is transmitted through the air?
For more information: The Latest Health-Related Hoaxes And Rumors
In the early 1990s, scientists reported that IL-10, a signaling protein excreted by activated immune cells, was essential for the maturation of B lymphocytes. That is, add IL-10 in culture, and naive, undifferentiated B cells mature; deprive the cells of the protein, and no differentiation occurs. But, as often happens in science, even the most straightforward discoveries turn out not to be so straightforward. In the latest issue of the journal Blood, scientists report for the first time that another protein called TIMP-1 seems to switch on the expression of IL-10 in normal B cells and B-cell non-Hodgkin lymphoma.
For more information: Scientists Report New Finding In Development Of B Cells
Results from a new study have found that a nicotine-free drug, bupropion hydrochloride SR (Zyban), was significantly more effective than a placebo in helping smokers who were unwilling or unable to quit to first reduce their cigarette use and then eventually quit. Ultimately, the study may offer physicians an alternative approach in treating their tobacco-using patients who have the greatest difficulty in quitting.
For more information: University Of Minnesota Study Shows That Drug Therapy Helps Motivate Smokers To Cut Down And Quit
American Home Products
Corporation announced on Friday that Protonix ® IV intravenous
formulation has been approved by the US Food And Drug Administration (FDA)
for short-term treatment (seven to 10 days) of gastroesophageal reflux disease
(GERD) as an alternative to oral therapy in patients who are unable to
continue taking Protonix ® (pantoprazole sodium) Delayed-Release Tablets.
Protonix ® is the first proton pump inhibitor (PPI) in the US available in
both oral and intravenous formulations. Safety and efficacy of Protonix ®
IV for Injection as an initial treatment for GERD have not been
demonstrated. Protonix ® is marketed by Wyeth-Ayerst Laboratories -- the
pharmaceutical division of AHP.
For more information: FDA Approves New IV Treatment For Hospitalized Patients With Acid Reflux
Today's Vidyya articles are:
As always, we hope you enjoy the issue.